Literature DB >> 23611617

Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.

Jennifer Williams1, Harlan R Sayles, Jane L Meza, Patrick Sayre, Uriel Sandkovsky, Howard E Gendelman, Charles Flexner, Susan Swindells.   

Abstract

AIM: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy.
METHODS: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ(2) tests were used for comparisons of interest across groups.
RESULTS: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use.
CONCLUSION: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23611617      PMCID: PMC3987826          DOI: 10.2217/nnm.12.214

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  16 in total

1.  HIV drug resistance and HIV transmission risk behaviors among active injection drug users.

Authors:  Michael J Kozal; K Rivet Amico; Jennifer Chiarella; Deborah Cornman; William Fisher; Jeffrey Fisher; Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2005-09-01       Impact factor: 3.731

2.  The critical need for alternative antiretroviral formulations, and obstacles to their development.

Authors:  Susan Swindells; Charles Flexner; Courtney V Fletcher; Jeffrey M Jacobson
Journal:  J Infect Dis       Date:  2011-07-25       Impact factor: 5.226

3.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

4.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.

Authors: 
Journal:  HIV Clin Trials       Date:  2000 Jul-Aug

5.  Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

Authors:  Prasanta K Dash; Howard E Gendelman; Upal Roy; Shantanu Balkundi; Yazen Alnouti; Rodney L Mosley; Harris A Gelbard; Joellyn McMillan; Santhi Gorantla; Larisa Y Poluektova
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

Review 6.  HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.

Authors:  Didier Trono; Carine Van Lint; Christine Rouzioux; Eric Verdin; Françoise Barré-Sinoussi; Tae-Wook Chun; Nicolas Chomont
Journal:  Science       Date:  2010-07-09       Impact factor: 47.728

Review 7.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

Review 8.  Recent progress in nanotechnology for cancer therapy.

Authors:  Mu-Fei Tang; Lei Lei; Sheng-Rong Guo; Wen-Lin Huang
Journal:  Chin J Cancer       Date:  2010-09

Review 9.  Nanomedicine: promises and challenges for the future of public health.

Authors:  Michelle Pautler; Sara Brenner
Journal:  Int J Nanomedicine       Date:  2010-10-05

10.  Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

Authors:  Lieven Baert; Gerben van 't Klooster; Willy Dries; Marc François; Alfons Wouters; Esther Basstanie; Koen Iterbeke; Fred Stappers; Paul Stevens; Laurent Schueller; Pieter Van Remoortere; Guenter Kraus; Piet Wigerinck; Jan Rosier
Journal:  Eur J Pharm Biopharm       Date:  2009-03-27       Impact factor: 5.571

View more
  47 in total

Review 1.  The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.

Authors:  Upal Roy; Jesse Rodríguez; Paul Barber; José das Neves; Bruno Sarmento; Madhavan Nair
Journal:  Nanomedicine (Lond)       Date:  2015-09-24       Impact factor: 5.307

Review 2.  Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.

Authors:  Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner
Journal:  Lancet HIV       Date:  2019-12-20       Impact factor: 12.767

Review 3.  From design to the clinic: practical guidelines for translating cardiovascular nanomedicine.

Authors:  Iwona Cicha; Cédric Chauvierre; Isabelle Texier; Claudia Cabella; Josbert M Metselaar; János Szebeni; László Dézsi; Christoph Alexiou; François Rouzet; Gert Storm; Erik Stroes; Donald Bruce; Neil MacRitchie; Pasquale Maffia; Didier Letourneur
Journal:  Cardiovasc Res       Date:  2018-11-01       Impact factor: 10.787

4.  Long-acting HIV drugs advanced to overcome adherence challenge.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2014-04       Impact factor: 53.440

5.  Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.

Authors:  John M Cortez; Rafaela Quintero; John A Moss; Martin Beliveau; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

6.  Interest of Youth Living With HIV in Long-Acting Antiretrovirals.

Authors:  Ethel D Weld; Md Sohel Rana; Ronald H Dallas; Andres F Camacho-Gonzalez; Patrick Ryscavage; Aditya H Gaur; Rana Chakraborty; Susan Swindells; Charles Flexner; Allison L Agwu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

7.  Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.

Authors:  Manjula Gunawardana; Mariana Remedios-Chan; Christine S Miller; Rob Fanter; Flora Yang; Mark A Marzinke; Craig W Hendrix; Martin Beliveau; John A Moss; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

8.  Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

Authors:  S Swindells; M Siccardi; S E Barrett; D B Olsen; J A Grobler; A T Podany; E Nuermberger; P Kim; C E Barry; A Owen; D Hazuda; C Flexner
Journal:  Int J Tuberc Lung Dis       Date:  2018-02-01       Impact factor: 2.373

9.  Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.

Authors:  Pavan Puligujja; Shantanu S Balkundi; Lindsey M Kendrick; Hannah M Baldridge; James R Hilaire; Aditya N Bade; Prasanta K Dash; Gang Zhang; Larisa Y Poluektova; Santhi Gorantla; Xin-Ming Liu; Tianlei Ying; Yang Feng; Yanping Wang; Dimiter S Dimitrov; JoEllyn M McMillan; Howard E Gendelman
Journal:  Biomaterials       Date:  2014-12-09       Impact factor: 12.479

10.  Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.

Authors:  Lisa A McConnachie; Loren M Kinman; Josefin Koehn; John C Kraft; Sarah Lane; Wonsok Lee; Ann C Collier; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2018-03-13       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.